Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
18.28 EUR | +0.44% | +2.35% | +10.05% |
Apr. 11 | Transcript : Fagron NV, Q1 2024 Sales/ Trading Statement Call, Apr 11, 2024 | |
Apr. 11 | Fagron Reports Revenue Results for the First Quarter Ended 31 March 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+10.05% | 1.42B | B | ||
+26.47% | 664B | C+ | ||
+24.88% | 567B | B | ||
-6.33% | 354B | C+ | ||
+19.35% | 330B | B- | ||
+4.23% | 286B | C+ | ||
+13.96% | 234B | B+ | ||
+4.58% | 199B | B- | ||
-9.86% | 196B | A+ | ||
-4.04% | 148B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- FAGR Stock
- Ratings Fagron N.V.